First delivered to the market in 2010, TomoDirect is a standard feature on the TomoHD™ Treatment System. It is optimized for delivering radiation at fixed angles, making it highly efficient for whole breast radiotherapy and other cases where select beam angles are most appropriate. Global adoption continues, with over 75 percent of system orders in the past six months including TomoDirect.
The Institute for Image-Guided RadioTherapy (IIGRT) in Westchester, Rye, New York is one of the first centers in the world to offer TomoDirect treatments. IIGRT performs both whole breast and accelerated partial breast irradiation (APBI) with TomoDirect.
“IIGRT has been using theTomoTherapy System since 2007 and we have significantly increased our treatment capacity with the addition of TomoDirect last year, because we can now offer TomoTherapy to an expanded patient population,” said Dr. Daniel Fass, director of IIGRT. “TomoDirect offers a highly accurate and convenient method for delivering APBI. This allows us to offer many breast cancer patients a shorter course of high quality radiation therapy treatments. We also use TomoDirect for conventional breast treatments when it offers a dosimetric advantage over Helical TomoTherapy.”
Accuray’s TomoHD Treatment System is a comprehensive solution that efficiently handles clinical indications of any complexity. The system offers both TomoDirect and TomoHelical treatment modes to allow clinicians to deliver treatment options for a range of clinical indications and enables daily 3D CT imaging of every patient, prior to each treatment, to maximize treatment accuracy. The TomoDirect modality is efficient in applying multiple targeted radiation beams to the tumor for more routine cases while TomoHelical is designed for more complex cases, delivering radiation throughout multiple 360 degree gantry rotations.
“The combination of TomoDirect and TomoHelical on the TomoHD System creates a single efficient and clinically flexible radiation therapy treatment solution,” said Omar Dawood M.D., M.P.H., senior vice president, Global Medical Affairs, Accuray Incorporated. “By expanding the reach of TomoTherapy technology, the addition of TomoDirect allows physicians to offer the highest quality treatments tailored for each individual patient’s specific clinical needs. The increase in global adoption of TomoDirect is a testament to the clinical benefits of the technology.”
About Accuray
Accuray Incorporated, based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the Company's technologies and more than 582 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
